Interpace Biosciences (Interpace Biosciences) EV-to-Revenue : 0.44 (As of May. 02, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Interpace Biosciences's enterprise value is $13.65 Mil. Interpace Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $31.14 Mil. Therefore, Interpace Biosciences's EV-to-Revenue for today is 0.44.

The historical rank and industry rank for Interpace Biosciences's EV-to-Revenue or its related term are showing as below:

IDXG' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.27 Med: 0.7 Max: 22.48
Current: 0.44

During the past 13 years, the highest EV-to-Revenue of Interpace Biosciences was 22.48. The lowest was -1.27. And the median was 0.70.

IDXG's EV-to-Revenue is ranked better than
89.82% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.03 vs IDXG: 0.44

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-02), Interpace Biosciences's stock price is $1.36. Interpace Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.18. Therefore, Interpace Biosciences's PS Ratio for today is 0.19.

Interpace Biosciences EV-to-Revenue Historical Data

The historical data trend for Interpace Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences EV-to-Revenue Chart

Interpace Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

2.09

0.45

1.19

0.49

0.31

Interpace Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															0.49	0.44	0.39	0.43	0.31

Competitive Comparison of Interpace Biosciences's EV-to-Revenue

For the Diagnostics & Research subindustry, Interpace Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Interpace Biosciences's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's EV-to-Revenue falls into.

Interpace Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Interpace Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	13.646	/	31.135
	=	0.44

Interpace Biosciences's current Enterprise Value is $13.65 Mil.
Interpace Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.14 Mil.

Interpace Biosciences (OTCPK:IDXG) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Interpace Biosciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.36	/	7.178
	=	0.19

Interpace Biosciences's share price for today is $1.36.
Interpace Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.18.

Interpace Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences (Interpace Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

PF42:Germany

Address

300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Executives

Christopher Mccarthy	officer: Principal Financial Officer	C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal	director	2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell	director, officer: President and CEO	1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin	10 percent owner	2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel	officer: Chief Financial Officer	REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca	director	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan	director	C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p.	10 percent owner	2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy	director	2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership	10 percent owner	55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev	director, 10 percent owner	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg	officer: Chief Accounting Officer	INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard	officer: Chief Commerical Officer	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054